Skip to main content
Log in

Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

From 1990 to 1996, 607 previously untreated, node-negative, invasive breast carcinomas were sampled by a pathologist for flow-cytometric DNA analysis. The aim of the present work was to study the correlations between flow cytometric results obtained thanks to the American Consensus (AC) guidelines of 1993 and the established clinico-pathological prognostic factors (T, grade, receptors), and despite a short global follow-up (mean of 4 years), to correlate flow cytometry with the outcome of the patients. In this study S-phase fraction (SPF) correlated strongly with tumor size, histological grade, lack of steroid receptors, histological type and was together with the mitotic activity a paramount prognostic factor even after multivariate analysis. This study compared also the technical criteria proposed by the AC with our own more stringent ones and concluded that the criteria of the AC are relevant and allow, thanks to the use of tertiles in the reporting of SPF values, a comparison of values obtained by different teams. Our review of the literature, focused on series using fresh material, enabled us to show that there is a rather wide agreement concerning the relationship between SPF and prognosis most often after multivariate analysis. This despite the lack of standardization in the design of the studies (implementation of the technical steps or reporting of results). When estimated from fresh or frozen material following AC’s guidelines, SPF along with mitotic activity should become a prognostic factor used in the daily practice by oncologists in the management of breast carcinomas.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Page DL: Prognosis and breast cancer. Recognition of lethal and favorable prognostic types. Am J Surg Pathol 15: 334–349, 1991

    Google Scholar 

  2. Clark GM, McGuire WL: Steroid receptors and other prognostic factors in primary breast cancer. Semin Oncol 15 (2 suppl 1): 10–25, 1988

    Google Scholar 

  3. Allred DC, Harvey JM, Berardo M, Clark GM: Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol 11: 155–168, 1998

    PubMed  Google Scholar 

  4. Bonadonna G, Valagussa P: Systemic therapy in resectable breast cancer. Hematol Oncol Clin North Am 3: 727–742, 1989

    PubMed  Google Scholar 

  5. Pritchard KI: Systemic adjuvant therapy for node-negative breast cancer: proven or premature. Ann Intern Med 111: 1–4, 1989

    PubMed  Google Scholar 

  6. Harris J, MorrowM, Norton L: Malignant tumors of the breast. In: De Vita VT, JR Hellman S, Rosenberg SA (eds) Cancer: Principles and Practice of Oncology, 5th edn, Lippincott Raven, Philadelphia, 1997, pp. 1591–1592

    Google Scholar 

  7. Shankey TV, Rabinovitch PS, Bagwell B, Bauer KD, Duque R, Hedley DW, Mayall BH, Wheeless LL: Guidelines for the implementation of clinical DNA flow cytometry. Cytometry 14: 472–477, 1993

    PubMed  Google Scholar 

  8. Hedley DW, Clark GM, Cornelisse CJ, Killander D, Kute T, Merkel D: Consensus review of the clinical utility of DNA cytometry in carcinoma of the breast. Cytometry 14: 482–448, 1993

    PubMed  Google Scholar 

  9. Bloom HCG, Richardson WW: Histological grading and prognosis in breast cancer: A study of 1409 cases of which 359 have been followed for 15 years. Br J Cancer 11: 359–376, 1957

    PubMed  Google Scholar 

  10. STATA Reference Manual. 5th Edn, 4th release. College Station, Texas, Stata Corporation, 1995

  11. Bergers E, van Diest PJ, Baak JPA: Cell cycle analysis of 932 flow cytometric DNA histograms of fresh frozen breast carcinoma material. Correlations between flow cytometric, clinical, and pathologic variables. Cancer 77: 2258–2266, 1996

    PubMed  Google Scholar 

  12. Stal O, Brisfors A, Carstensen J, Ferraud L, Hatschek T, Nordenskjöld B, and the Southeast Sweden Breast Cancer Group: Relationships of DNA ploidy, S-phase fraction and hormone receptor status to tumor stage in breast cancers detected by population screening. Int J Cancer 51: 28–33, 1992

    PubMed  Google Scholar 

  13. Lawry J, Rogers K, Duncan JL, Potter CW: The identification of informative parameters in the flow cytometric analysis of breast carcinomas. Eur J Cancer 29A: 719–723, 1993

    PubMed  Google Scholar 

  14. Wenger CR, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian MR, Harrington D, Clark GM, McGuire WL: DNA ploidy, S-phase, and steroid receptors in more than 127,000 breast cancer patients. Breast Cancer Res Treat 28: 9–20, 1993

    PubMed  Google Scholar 

  15. Stal O, Carstensen J, Hatschek T, Nordenskjöld B: Significance of S-phase fraction and hormone receptor content in the management of young breast cancer patients. Br J Cancer 66: 706–711, 1992

    PubMed  Google Scholar 

  16. Chassevent A, Geslin J, Bertrand G, Cellier P, Daver A, Gamelin E, Larra F, Minier JF: Place de I'analyse d'ADN par cytométrie en flux dans l'évaluation du pronostic des cancers du sein. Bull Cancer 77 (suppl 1): 149S–154S, 1990

    Google Scholar 

  17. Visscher DW, Zarbo RJ, Jacobsen G, Kambouris A, Talpos G, Sakr W, Crissman JD: Multiparametric deoxyribonucleic acid DNA cell cycle analysis of breast carcinomas by flow cytometry. Lab Inv 62: 370–378, 1990

    Google Scholar 

  18. Del Bino G, Silvestrini R, Zucconi MR, Marchese G, Valentinis B, Di Fronzo G, Andreola S: DNA ploidy of human breast cancer. Anal Cell Pathol 1: 215–223, 1989

    PubMed  Google Scholar 

  19. Christov K, Milev A, Todorov V: DNA aneuploidy and cell proliferation in breast tumors. Cancer 64: 673–679, 1989

    PubMed  Google Scholar 

  20. Spyratos F, Brifford M, Gentile A, Brunet M, Brault C, Desplace A: Flow cytometric study of DNA distribution in cytopunctures of benign and malignant breast lesions. Anal Quant Cytol Histol 9: 485–494, 1987

    PubMed  Google Scholar 

  21. Jakobsen A, Skovgaard Poulsen H, Lindegaard Madsen E, Elleaek Petersen S, Hansen Sommer H: Ploidy level of human breast carcinoma: relation to histopathological features and hormone receptor content. Acta Radiological Oncol 23: 103–107, 1984

    Google Scholar 

  22. Frierson IF: Grade and flow cytometric analysis of ploidy for infiltrating ductal carcinomas. Hum Pathol 24: 24–29, 1993

    PubMed  Google Scholar 

  23. Leonardi E, Cristofori A, Caffo O, Dalla Palma P: Cytometric DNA analysis and prognostic biomarkers in breast carcinoma: Expression of p53 product in the different ploidy classes. An Cell Pathol 15: 31–45, 1997

    Google Scholar 

  24. Baldetorp B, Ferno M, Fallenius A, Fallenius-Vecchi G, Idvall I, Olsson H, Sigurdsson H, Akerman M, Killander D: Image cytometric DNA analysis in human breast cancer analysis may add prognostic information in diploid cases with low S-phase fraction by flow cytometry. Cytometry 113: 577–585, 1992

    Google Scholar 

  25. Dressler LG, Seamer LC, Owens MA, Clark GM, McGuire WL: DNA proliferative flow cytometry and prognostic factors in 1331 frozen breast cancer specimens. Cancer 61: 420–427, 1988

    PubMed  Google Scholar 

  26. Stal O, Wingren S, Carstensen J, Rutqvist LE, Skoog L, Klintenberg C, Nordenskjöld B: Prognostic value of DNA ploidy and S-phase fraction in relation to estrogen receptor content and clinicopathological variables in primary breast cancer: Eur J Cancer Clin Oncol 25: 301–309, 1989

    PubMed  Google Scholar 

  27. Ottestad L, Pettersen EO, Nesland JM, Hannisdal E, Fossa SD, Tveit KM: Flow cytometric DNA analysis as prognostic factor in human breast carcinoma. Pathol Res Pract 189: 405–410, 1993

    PubMed  Google Scholar 

  28. Stal O, Brisfors A, Carstensen J, Ferraud L, Hatshek T, Nordenskjöld B: Interrelations between cellular DNA content, S-phase fraction, hormone receptors status and age in primary breast cancer. Acta Oncol 31: 283–292, 1992

    PubMed  Google Scholar 

  29. Fernö M, Baldetorp B, Borg A, Olsson H, Sigurdsson H, Killander D: Flow cytometric DNA index and S-phase fraction in breast cancer in relation to other prognostic variables and to clinical outcome. Acta Oncol 31: 157–165, 1992

    PubMed  Google Scholar 

  30. Horsfall DJ, Tilley WD, Orell SR, Marshall VR, Cant EL: Relationship between ploidy and steroid hormone receptors in primary invasive breast cancer. Br J Cancer 53: 23–28, 1986

    PubMed  Google Scholar 

  31. Falkmer UG, Hagmar T, Auer G: Efficacy of combined image and flow cytometric DNA assessments in human breast cancer: a methodological study based on a routine histopathological material of 2024 excised tumor specimens: Annal Cell Pathol 2: 297–312, 1990

    Google Scholar 

  32. Ewers SB, Attewell R, Baldetorp B, Borg A, Langstrom E, Killander D: Prognostic potential of flow cytometric Sphase and ploidy prospectively determined in primary breast carcinomas. Breast Cancer Res Treat 20: 93–108, 1991

    Google Scholar 

  33. Balslev I, Christensen IJ, Bruun Rasmussen B, Larsen JK, Lykkesfeldt AE, Thorpe SM, Rose C, Briand P, Mouridsen HT: Flow cytometric DNA ploidy defines patients with poor prognosis in node-negative breast cancer. Int J Cancer 56: 16–25, 1994

    PubMed  Google Scholar 

  34. Lykkesfeldt AE, Balslev I, Christensen IJ, Larsen JK, Molgaard H, Rasmussen BB, Thorpe S, Rose C: DNA ploidy and S-phase fraction in primary breast carcinomas in relation to prognostic factors and survival for premenopausal patients at high risk for recurrent disease. Acta Oncologica 6: 749–756, 1988

    Google Scholar 

  35. Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Fernö M, Killander D, Olsson H, Ranstam J: Flow cytometry in primary breast cancer: improving the prognostic value of the fraction of cells in the S-phase by optimal categorization of cut-off levels. Br J Cancer 62: 786–790, 1990

    PubMed  Google Scholar 

  36. Sigurdsson H, Baldetorp B, Borg A, Dalberg M, Fernö M, Killander D, Olsson H: Indicators of prognosis in nodenegative breast cancer. The New Engl J Med 322: 1045–1053, 1990

    Google Scholar 

  37. Klintenberg C, Stal O, Nordenskjöld B, Wallgren A, Arvidsson S, Skoog L: Proliferative index, cytosol estrogen receptor and axillary node status as prognostic predictors in human mammary carcinoma. Breast Cancer Res Treat 7 (suppl): 99–106, 1986

    Google Scholar 

  38. Stal O, Klintenberg C, Franzen G, Risberg B, Arvidsson S, Bjelkenkrantz K, Skoog L, Nordenskjöld B: A comparison of static cytofluorometry and flow cytometry for the estimation of ploidy and DNA replication in human breast cancer. Breast Cancer Res Treat 7: 15–22, 1986

    PubMed  Google Scholar 

  39. Clark GM, Dressler LG, Owens MA, Pounds G, Oldaker T, Pandian MR, Harrington D, McGuire WL: Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. New Engl J Med 320: 627–633, 1989

    PubMed  Google Scholar 

  40. Muss HB, Kute TE, Case LD, Smith R, Booher C, Long R, Kammire L, Gregory B, Brockschmidt JK: The relation of flow cytometry to clinical and biologic characteristics in women with node negative primary breast cancer. Cancer 64: 1894–1900, 1989

    PubMed  Google Scholar 

  41. Zanon C, Durando A, Geuna M, Clara R, Mobiglia A, Massobrio M, Palestro G, Pourshayesteh A: Flow cytometry in breast cancer. Am J Clin Oncol 21: 392–397, 1998

    PubMed  Google Scholar 

  42. Silvestrini R, Daidone MG, Del Bino G, Mastore M, Luisi A, Di Fronzo G, Boracchi P: Prognostic significance of proliferative activity and ploidy in node-negative breast cancers. Annals Oncol 4: 213–219, 1993

    Google Scholar 

  43. Remvikos Y, Gerbault-Seureau, Magdalénat H, Prieur M, Dutrillaux B: Proliferative activity of breast cancers increases in the course of genetic evolution as defined by cytogenetic analysis. Breast Cancer Res Treat 23: 43–49, 1992

    PubMed  Google Scholar 

  44. Meyer JS, Province MA: S-phase fraction and nuclear size in long term prognosis of patients with breast cancer. Cancer 74: 2287–2289, 1994

    PubMed  Google Scholar 

  45. Clark GM, Wenger CW, Beardslee S, Owens MA, Pounds G, Oldaker T, Vendely P, Pandian NM, Harrington D, McGuire WL: How to integrate steroid hormone receptor, flow cytometric, and other prognostic information in regard to primary breast cancer. Cancer 71: 2157–2162, 1993

    PubMed  Google Scholar 

  46. McDivitt RW, Stone KR, Craig RB, Palmer JO, Meyer JS, Bauer WC: A proposed classification of breast cancer based on kinetic information: derived from a comparison of risk factors in 168 primary operable breast cancers. Cancer 57: 269–276, 1986

    PubMed  Google Scholar 

  47. Wenger CR, Clark GM: S-phase fraction and breast cancer: a decade of experience. Breast Cancer Res Treat 51: 255–261, 1998

    PubMed  Google Scholar 

  48. Clinical Practice guidelines for the use of tumor markers in breast and colorectal cancer (ASCO). J Clin Oncol 14: 2843–2877, 1996

  49. 1997 update of recommendations for the use of tumor markers in breast and colorectal cancer (ASCO). J Clin Oncol 16: 793–795, 1998

Download references

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Michels, JJ., Duigou, F. & Marnay, J. Flow cytometry in primary breast carcinomas. Prognostic impact of proliferative activity. Breast Cancer Res Treat 62, 117–126 (2000). https://doi.org/10.1023/A:1006451908322

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1006451908322

Navigation